These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 33012873)

  • 1. Asenapine Transdermal Patch for the Management of Schizophrenia.
    Zhou M; Derakhshanian S; Rath A; Bertrand S; DeGraw C; Barlow R; Menard A; Kaye AM; Hasoon J; Cornett EM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2020 Sep; 50(4):60-82. PubMed ID: 33012873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the clinical efficacy of asenapine in schizophrenia.
    Minassian A; Young JW
    Expert Opin Pharmacother; 2010 Aug; 11(12):2107-15. PubMed ID: 20642375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In brief: An asenapine patch (Secuado) for schizophrenia.
    Med Lett Drugs Ther; 2021 Jan; 63(1615):7-8. PubMed ID: 33647000
    [No Abstract]   [Full Text] [Related]  

  • 5. Asenapine versus placebo for schizophrenia.
    Hay A; Byers A; Sereno M; Basra MK; Dutta S
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD011458. PubMed ID: 26599405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070).
    Suzuki K; Castelli M; Komaroff M; Starling B; Terahara T; Citrome L
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):286-294. PubMed ID: 33734167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia.
    McIntyre RS; Wong R
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):217-20. PubMed ID: 22182459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asenapine: a clinical review of a second-generation antipsychotic.
    Stoner SC; Pace HA
    Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal Asenapine in Schizophrenia: A Systematic Review.
    Carrithers B; El-Mallakh RS
    Patient Prefer Adherence; 2020; 14():1541-1551. PubMed ID: 32943849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review.
    Stepanova E; Grant B; Findling RL
    Paediatr Drugs; 2018 Apr; 20(2):121-134. PubMed ID: 29170943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asenapine: a new antipsychotic option.
    Henry JM; Fuller MA
    J Pharm Pract; 2011 Oct; 24(5):447-51. PubMed ID: 22156709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Optimization of Asenapine Sublingual Film Using QbD Approach.
    Dalal R; Shah J; Gorain B; Choudhury H; Jacob S; Mehta TA; Shah H; Nair AB
    AAPS PharmSciTech; 2021 Oct; 22(7):244. PubMed ID: 34608546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asenapine: an atypical antipsychotic with atypical formulations.
    Musselman M; Faden J; Citrome L
    Ther Adv Psychopharmacol; 2021; 11():20451253211035269. PubMed ID: 34540197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study.
    Citrome L; Walling DP; Zeni CM; Starling BR; Terahara T; Kuriki M; Park AS; Komaroff M
    J Clin Psychiatry; 2020 Dec; 82(1):. PubMed ID: 33326711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asenapine: a clinical overview.
    Potkin SG
    J Clin Psychiatry; 2011; 72 Suppl 1():14-8. PubMed ID: 22217438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asenapine: Pharmacological Aspects and Role in Psychiatric Disorders.
    Reyad AA; Mishriky R
    Psychiatr Danub; 2019 Jun; 31(2):157-161. PubMed ID: 31291219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asenapine pharmacokinetics and tolerability in a pediatric population.
    Dogterom P; Riesenberg R; de Greef R; Dennie J; Johnson M; Pilla Reddy V; Miltenburg AM; Findling RL; Jakate A; Carrothers TJ; Troyer MD
    Drug Des Devel Ther; 2018; 12():2677-2693. PubMed ID: 30214156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asenapine: a review of acute and extension phase data in bipolar disorder.
    McIntyre RS
    CNS Neurosci Ther; 2011 Dec; 17(6):645-8. PubMed ID: 20950326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of long acting invasomal nanovesicles for improved transdermal permeation and bioavailability of asenapine maleate for the chronic treatment of schizophrenia.
    El-Tokhy FS; Abdel-Mottaleb MMA; El-Ghany EA; Geneidi AS
    Int J Pharm; 2021 Oct; 608():121080. PubMed ID: 34506923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.